Navigation Links
Jazz Pharmaceuticals Announces Third Quarter 2013 Financial Results
Date:11/5/2013

owing updated 2013 guidance:Revenues

$867-$877 millionTotal Net Product Sales

$860-$870 million-Xyrem Net Sales

$565-$570 million-Erwinaze/Erwinase Net Sales

$173-$178 millionAdjusted Gross Margin %1,3

88-90%Adjusted Combined SG&A and R&D Expenses2,3

$275-$280 millionGAAP Net Income Per Diluted Share

$3.63-$3.79Adjusted Net Income Per Diluted Share3

$6.30-$6.401.

Excludes $4 million of acquisition accounting inventory fair value step-up adjustments and $3 million in share-based compensation expense from estimated GAAP gross margin of 87-89%.2.

Excludes $42 million of share-based compensation expense, $15 million related to a change in fair value of contingent consideration, $3 million of depreciation expense, $5 million of upfront license fees and $3 million of transaction, integration and restructuring costs from estimated GAAP combined SG&A and R&D expenses of $343-$348 million.3.

See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the tables accompanying this press release.Conference Call DetailsJazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EST (9:30 p.m. GMT) to provide a business update and discuss its third quarter 2013 results and updated 2013 financial guidance. The live webcast may be accessed from the Investors & Media section of the company's website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing +1 800 591 6942 in the U.S., or +1 617 614 4909 outside the U.S., and entering passcode 48257479.

A replay of the conference call will be availabl
'/>"/>

SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
2. Aquavit Pharmaceuticals Adds New Advanced Drug Delivery Technology to Product Portfolio
3. Jazz Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference on November 12
4. Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
5. Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
6. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
7. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
8. Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers
9. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
11. Cumberland Pharmaceuticals To Announce Third Quarter 2013 Financial Results On November 5, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015   ICD-10 Charts ... months of development, it has officially launched its ... Charts Training Academy and the new 4 Step ... well as all other ICD-10 Charts resources and ... in America, completely free-of-charge.  With the release of ...
(Date:7/7/2015)... 2015 Research and ... the "Elemental Analysis Market by Type (Organic, ... Application (Life Sciences, Food and Beverage Testing, Environment ... report to their offering. The ... types, technologies, and applications. By type, the market ...
(Date:7/7/2015)... and FREMONT, Calif. , July 7, ... South Korea and Velos, Inc. have entered into ... eResearch for cancer research nationally throughout South Korea ... The recent agreement signing was accompanied by a two day ... , South Korea.  National Cancer Center President ...
Breaking Medicine Technology:ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 2ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 4Elemental Analysis (Organic, Inorganic) Market 2015 - Analysis & Global Forecasts to 2020 2National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 2National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 3
... Oct. 6 According to Millennium Research Group ... intelligence, growth in the $2 billion US cardiac ... the expanded approval of Boston Scientific,s chronic resynchronization ... I and II patients. The New ...
... Oct. 6 e-MDs, an industry leader in ... (EHRs) and practice management (PM) solutions,  congratulates  the ... Family Medicine of Fort Collins, CO, for their ... of Excellence recipients.  The Healthcare Information and Management ...
Cached Medicine Technology:Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 2Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 3e-MDs Clients Win HIMSS Davies Awards of Excellence 2e-MDs Clients Win HIMSS Davies Awards of Excellence 3e-MDs Clients Win HIMSS Davies Awards of Excellence 4
(Date:7/7/2015)... ... July 07, 2015 , ... The United States Centers for Disease Control ... , and the Multicultural AIDS Coalition $3.78 million for a five-year HIV ... with men (MSM) and transgender women, the groups at highest risk of HIV ...
(Date:7/7/2015)... ... July 07, 2015 , ... Quadrino Law Group is pleased to announce ... New York 11747. The new facility is a state of the art building, ... Richard Quadrino, the firm's CEO and founder, said, "We are pleased to service our ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today ... to access its antibody combination therapy (ACT) technology platform. The platform has ...
(Date:7/7/2015)... ... July 07, 2015 , ... Summer is a great time ... so Amica Insurance is sharing some safety tips. , Jean Tapley, senior wellness coordinator ... Leisure activities/sports, , Start slowly. Going from no activity to ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, the ... Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted to join ... underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a global ...
Breaking Medicine News(10 mins):Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2
... researchers older people have a less chance of surviving lung ... in time. On an average older people are more susceptible ... a ventilator.// What's not been clear is whether they do ... new study suggests that age is indeed a factor in ...
... of serotonin-raising drugs like antidepressants and slimming pills in ... of durgs is by increasing the levels of serotonin, ... body.// Examples include diet pills, anti-migraine drugs and some ... Health welfare hospital, warn of the potential dangers of ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... women whose jobs require too much exposure to solvents ... have chilren with defective eyesight. Head researcher Dr. Gideon ... of Occupational health. ,They found that poor ... mothers were frequently exposed to organic solvents at work ...
... School researchers have discovered nearly all the genes responsible ... blinding diseases.Macular degeneration affects 20 per cent of people ... photoreceptor genes expressed int he retinal cells, which was ... for preserving and restoring the vision of those affected.// ...
... People who suffer from asthma, particularly women, may have ... period of 30 years, researchers studied almost 100,000 patients ... of the patients showed any signs of cancer at ... second year after asthma diagnosis until the last day ...
Cached Medicine News:Health News:Genes for Vision discovered 2
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Rad-5 signal extraction pulse oximeter™...
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: